Conquering Diseases

Study Of Adding An Investigational Drug To Treat A Type Of Non-Hodgkin Lymphoma


People with a type of Diffuse Large B-Cell Lymphoma called "Activated B Cell" that did not get better with treatment or has returned after previous treatment sought for a study of whether adding in an additional investigational drug makes the therapy better, the same or worse than the usual approach.


The purpose of this study is to compare the effects on people who receive the investigational drug in addition to the usual therapy to people who will receive a pill that looks like the study drug but contains no medication (placebo). Half the volunteers for this study will take the investigational drug and half will get the placebo for a year following treatment with chemotherapy and autologous hematopoietic stem cell transplantation (AutoHCT).

What we're hoping for

We hope that adding the investigational drug will improve outcomes and not cause more side effects for people with a type of non-Hodgkin lymphoma (diffuse large B-Cell lymphoma) called "Activated B Cell".

Additional Information Identifier: NCT02443077

 Principal Investigator

Jan  Cerny, MD, PhD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655